0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Reviews |

Leukocyte Reduction in Blood Component Therapy

Thomas A. Lane, MD; Kenneth C. Anderson, MD; Lawrence T. Goodnough, MD; Sanford Kurtz, MD; Gary Moroff, PhD; Patricia T. Pisciotto, MD; Merlin Sayers, MD, PhD; and Leslie E. Silberstein, MD
[+] Article and Author Information

Grant Support: In part by the American Association of Blood Banks.

Requests for Reprints: Thomas A. Lane, MD, UCSD School of Medicine, Department of Pathology 0612, 9500 Gilman Drive, La Jolla, CA 92093.

Current Author Addresses: Dr. Lane: Department of Pathology 0612, UCSD School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093.

Dr. Anderson: Dana-Farber Institute, 44 Binney Street, Boston, MA 02115.

Dr. Goodnough: Department of Medicine, University Hospitals, 2074 Abigton Road, Cleveland, OH 44106.

Dr. Kurtz: Lahey Clinic, 41 Mall Road, Box 541, Burlington, MA 01805.

Dr. Moroff: American Red Cross, Jerome Holland Laboratory, 15601 Crabb's Branch Way, Rockville, MD 20855.

Dr. Pisciotto: University of Connecticut Health Center, Department of Laboratory Medicine, C2058, Farmington, CT 06030.

Dr. Sayers: Puget Sound Blood Center and Program, 921 Terry Avenue, Seattle, WA 98104-1256.

Dr. Silberstein: Hospital of the University of Pennsylvania, Blood Bank, 3400 Spruce Street, 6-60, Founders Pavilion, Philadelphia, PA 19104-4283.


©1992 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1992;117(2):151-162. doi:10.7326/0003-4819-117-2-151
Text Size: A A A

Purpose: To review methods of preventing or minimizing the adverse effects associated with the transfusion of passenger leukocytes present in cellular blood components and to define groups of patients who are at risk for adverse effects.

Data Sources: English-language articles on transfusion medicine.

Study Selection: Original reports describing the pathogenesis of leukocyte-induced adverse effects in transfusion recipients and the influence of leukocytereduced blood components on these effects.

Data Extraction: Evaluation of the diagnosis, transfusion history, and treatment of the study patients; the methods and results of leukocyte reduction; and specific outcomes, including development of alloimmunization to leukocytes, febrile reactions to transfusion, and platelet refractoriness.

▪ Data Synthesis: Passenger leukocytes are the chief cause of alloimmunization to human leukocyte antigen (HLA) and leukocyte-specific antigens in transfusion recipients. Alloimmunization may result in febrile transfusion reactions, platelet refractoriness, and acute lung injury. Leukocytes are also the vector for transfusionassociated cytomegalovirus infection. Technologic advances in the leukocyte reduction of cellular blood components have made it possible to reduce the number of leukocytes to fewer than 107 per transfusion. Findings suggest that the use of leukocyte-reduced cellular blood components may minimize or prevent recurrent febrile reactions and alloimmunization to leukocyte antigens. Cytomegalovirus may not be transmitted by blood components containing fewer than 107 leukocytes.

Conclusions: Leukocyte reduction in red blood cell and platelet transfusions using third-generation filters is indicated for selected patients who are likely to receive long-term transfusion support, to prevent recurrent febrile reactions and to prevent or delay alloimmunization to leukocyte antigens. Leukocyte-depleted transfusions may also be indicated to delay or prevent refractoriness to platelet transfusion.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)